[1]苏应瑞,查金顺,周竟雄,等.131Ⅰ治疗甲亢性心脏病患者尿脑钠肽水平变化的研究[J].国际放射医学核医学杂志,2012,36(6):371-375.[doi:10.3760/cma.j.issn.1673-4114.2012.06.012]
　SU Ying-rui,ZHA Jin-shun,ZHOU Jing-xiong,et al.The dynamic changes of brain natriuretic peptide level in patients with hyperthyroid heart disease after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):371-375.[doi:10.3760/cma.j.issn.1673-4114.2012.06.012]
点击复制

131Ⅰ治疗甲亢性心脏病患者尿脑钠肽水平变化的研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第6期
页码:
371-375
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The dynamic changes of brain natriuretic peptide level in patients with hyperthyroid heart disease after 131Ⅰ therapy
作者:
苏应瑞1;  查金顺1;  周竟雄2;  林夏鸿2;  许朝祥3;  王耀国3;  杜心清3
1. 福建医科大学附属第二医院核医学科, 泉州 362000;
2. 福建医科大学附属第二医院内分泌科, 泉州 362000;
3. 福建医科大学附属第二医院心内科, 泉州 362000
Author(s):
SU Ying-rui1;  ZHA Jin-shun1;  ZHOU Jing-xiong2;  LIN Xia-hong2;  XU Chao-xiang3;  WANG Yao-guo3;  DU Xin-qing3
Department of Nuclear Medicine, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
关键词:
甲亢性心脏病; 碘放射性同位素; 利钠肽; 脑; 尿液分析
Keywords:
Hyperthyroid heart disease; Iodine Radioisotope; Natriuretic peptide; Brain; Urinalysis
DOI:
10.3760/cma.j.issn.1673-4114.2012.06.012
摘要:
目的 探讨尿液脑钠肽水平的测定在131Ⅰ治疗甲状腺功能亢进性心脏病(甲心病)中的应用价值。方法 采用化学发光法检测111例接受131Ⅰ治疗的甲状腺功能亢进症(甲亢)患者和30名健康对照者的血浆和尿液脑钠肽浓度以及血清游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)水平。将111例甲亢患者分为单纯甲亢组(51例)和甲心病组(60例),并对甲心病组患者按照纽约心脏病学会(NYHA)标准对其心功能进行分级,其中,NYHA Ⅰ~Ⅱ级(A组)37例、NYHAⅢ~Ⅳ级(B组)23例。对正常对照组及131Ⅰ治疗前后各组患者的血浆和尿液脑钠肽水平以及FT3、FT4水平进行比较分析。结果 A、B两组甲心病患者治疗前血浆和尿液脑钠肽水平均显着高于单纯甲亢组(血浆:t=8.98、9.52,P均<0.01;尿液:t=10.83、12.73,P均<0.01)和正常对照组(血浆:t=8.97、9.52,P均<0.01;尿液:t=9.21、5.64,P均<0.01);甲心病B组131Ⅰ治疗前、治疗后6个月、12个月的血浆、尿液脑钠肽水平均明显高于甲心病A组(血浆:t=5.98、5.87、6.35,P均<0.01;尿液:t=4.33、4.09、5.02,P均<0.01)。随着心功能不全程度的加重,尿液脑钠肽水平逐渐升高,与血浆脑钠肽水平呈正相关(r=0.829,P<0.01);与NYHA分级呈正相关(r=0.751,P<0.01);与FT3、FT4水平呈正相关(FT3:r=0.635; FT4:r=0.672,P均<0.01)。结论 甲心病患者尿液脑钠肽水平随着心功能严重程度的增加而升高,尿液脑钠肽可以准确评价甲亢患者的心功能,可作为临床诊断、疗效观察以及预后判断的客观指标,与血浆脑钠肽具有相同的应用价值。
Abstract:
Objective To investigate the application value of urine brain natriuretic peptide(BNP) level in 131Ⅰ treatment of hyperthyroid heart disease. Methods One hundred and eleven hyperthyroidism patients who received 131Ⅰ therapy were divided into two groups, hyperthyroidism group(51 cases) and hyperthyroid heart disease group(60 cases), and 30 healthy subjects as control. Sixty patients in the hyperthyroid heart disease group all received ultrasonic cardiogram. The hyperthyroid heart disease group was divided into two subgroups according to New York Heart Association(NYHA) functional classification(hyperthyroid heart disease A subgroup and hyperthyroid heart disease B subgroup). The urine and serum BNP level and serum free triiodothyronine(FT3), free thyroxine(FT4) level were measured through chemiluminescence before and after therapy. Results The urine and serum BNP level before 131Ⅰ therapy of the hyperthyroid heart disease group were significantly higher than those of hyperthyroidism group(serum:t=8.98 and 9.52, both P<0.01;urine:t=10.83 and 12.73, both P<0.01)and the control group(serum:t=8.97 and 9.52, both P<0.01; urine:t=9.21 and 5.64, both P<0.01). The urine and serum BNP level before and 6, 12 months after 131Ⅰ therapy of the hyperthyroid heart disease A subgroup were significantly higher than those of hyperthyroid heart disease B subgroup(serum:t=5.98, 5.87 and 6.35, all P<0.01; serum:t=4.33, 4.09 and 5.02, all P<0.01). The urine level of BNP was gradually increased with the severity of cardiac insufficiency and it was positively correlated with the serum level of BNP(r=0.829, P<0.01), the NYHA functional classification(r=0.751, P<0.01) and the serum level of FT3 and FT4(FT3:r=0.635, P<0.01; FT4:r=0.672, P<0.01). Conclusions The urine BNP level of hyperthyroid heart disease patient increased with the severity of cardiac insufficiency. The urine BNP level could accurately reflect cardiac function of hyperthyroid heart disease patient, and could be used as objective indicator for clinical diagnosis, effective evaluation and prognosis evaluation. The urine BNP level has the same value as the serum BNP level.

参考文献/References:

[1] Januzzi JL,van Kimmenade R,Lainchbury J,et al.NT-ProBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure:an international pooled analysis of 1256 patients:the International Collaborative of NT-ProBNP Study.Eur Heart J,2006,27(3):330-337.
[2] 赵咏桔.甲状腺功能亢进症//陈家伦.临床内分泌学.上海:上海科学技术出版社,2011:337-362.
[3] No author.AHA medical/scientific statement.1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart.Circulation,1994,90(1):644-645.
[4] 蒋宁一,匡安仁,谭建,等.131I治疗Graves甲亢专家共识(2010年).中华核医学杂志,2010,30(5):346-351.
[5] 韦智晓,覃伟武,李俊红,等.131I碘治疗甲亢性心脏病763例临床分析.广西医科大学学报,2008,25(3):457-458.
[6] 高东升,沈彩云,董殿阶.钠尿肽的研究进展.医学综述,2008,14(1):121-123.
[7] 朱雪明,沈海英,冯萍,等.血浆脑钠素和心钠素在心力衰竭中的诊断价值及评价.中华检验医学杂志,2006,29(10):923-925.
[8] Linssen GC,Damman K,Hillege HL,et al.Urinary N-terminal prohormone brain natriuretic peptide excretion in patients with chronic heart failure.Circulation,2009,120(1):35-41.
[9] Michielsen EC,Bakker JA,Kimmenade RR,et al.The diagnostic value of serum and urinary NT-proBNP for heart failure.Ann Clin Biochem,2008,45(Pt 4):389-394.
[10] Cortes R,Rivera M,Salvador A,et al.Urinary B-type natriureticpeptide levels in the diagnosis and prognosis of heart failure.J CardFail,2007,13(7):549-555.
[11] Cortés R,Rivera M,Martinez Dolz L,et al.Urinary levels of B-type natriuretic peptide(BNP) and ventricular systolic dysfunction in heart failure patients.Rev Clin Esp,2009,209(4):168-175.
[12] Palmer SC,Endre ZH,Richards AM,et al.Characterization of NT-proBNP in human urine.Clin Chem,2009,55(6):1126-1134.
[13] 谢建忠.甲状腺功能亢进性心脏病误诊13例分析.中国实用内科杂志,2005,25(5):467-468.
[14] Christ-Crain M,Morgenthaler NG,Meier C,et al.Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states.Swiss Med Wkly,2005,135(37-38):549-554.
[15] 张承刚.甲状腺疾病核素治疗学.北京:原子能出版社,2003:226-228.
[16] 陆轶群,鲁燕,成兴波.甲亢性心脏病患者血浆B型脑钠肽水平的变化.苏州大学学报:医学版,2005,25(4):630-632.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]崔丽群,杨宝军,张香玲,等.131I治疗老年甲亢性心脏病的近期疗效观察[J].国际放射医学核医学杂志,2009,33(3):180.[doi:10.3760/cma.j.issn.1673-4114.2009.03.014]

备注/Memo

备注/Memo:
收稿日期:2012-09-17。
通讯作者:查金顺(Email:Zjs630805@126.com)
更新日期/Last Update: 1900-01-01